BRAF and adenocarcinoma: For BRAF (the third most mutated oncogene), a slightly higher variability in detected variants was observed compared to EGFR and KRAS. This included both codon 600 (38% of BRAF variants, 3.7% of adenocarcinomas, and 1.1% of SqCCs specifically) and codon 601 (5.4% of BRAF variants) variants known or suggested to be treatment predictive in malignant melanoma, but also variants in codons 466 (11%), 469 (5.4%), and 594 (22% of BRAF variants) for which the treatment predictive value to BRAF inhibitors are not fully elucidated (Supplementary Figure 2).